Not all magnesium supplements are created equal
Prescription volumes have surged, with GLP-1 users rising from 745 per 100,000 individuals in 2018 to 3,572 per 100,000 in 2023, indicating a 4.7x increase in adoption
However, its possible to mitigate these side effects by commencing with a lower dosage and gradually increasing it
Because fat is the slowest macronutrient to leave the stomach, and GLP-1 medications already delay gastric emptying
Oral semaglutide has been approved and recently marketed in Spain following evidence from the Phase 3 clinical trial program Peptide InnOvatioN for Early diabEtes tReatment (PIONEER)
Clinical trials are blunt about it: when people stop taking semaglutide or tirzepatide, a large share of the weight comes back, often within a year